Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
CNS and Neurological Disorders - Drug Targets is Scopus-indexed (Q1, CiteScore 7.3), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Bentham Science Publishers.
Checked against the index lists dated .
ISSN 1871-5273Verify ISSN ↗1996-3181Verify ISSN ↗
Publisher: Bentham Science Publishers
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology | 76 / 328 | 76th | Q1 |
| Neuroscience (all) | 30 / 112 | 73rd | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2006–present, best quartile Q1, CiteScore 7.3.
CNS and Neurological Disorders - Drug Targets is Q1 in Pharmacology (rank 76 of 328) and Q2 in Neuroscience (all) (rank 30 of 112), by CiteScore 2025.
CNS and Neurological Disorders - Drug Targets is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 7.3, which places it in quartile Q1 at the 76th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.789, quartile Q2, with an H-index of 105.
CNS and Neurological Disorders - Drug Targets is published by Bentham Science Publishers. Its print ISSN is 1871-5273 and its online ISSN is 1996-3181.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
CNS and Neurological Disorders - Drug Targets has an h-index of 115 and a 2-year mean of 2.19 citations per paper (OpenAlex). Its Scopus CiteScore is 7.3, quartile Q1. On 2-year citations it ranks #163 of 319 Scopus journals in Pharmacology.
CNS and Neurological Disorders - Drug Targets published 78 papers in 2025; its busiest recent year was 2021 with 151. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2026), authors are most often from India (51.9%), China (19.6%) and Iran (6.1%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.